Survival outcomes of adolescent and adult patients with non-seminomatous testicular germ-cell tumors: A population-based study. Issue 6 (December 2016)

• Record Type: Journal Article
• Authors: Amini, Arya; Waxweiler, Timothy V.; Maroni, Paul D.; Kessler, Elizabeth R.; Cost, Carrye R.; Greffe, Brian S.; Garrington, Timothy P.; Liu, Arthur K.; Cost, Nicholas G.
• Is Part Of: Journal of pediatric urology. Volume 12:Issue 6(2016)
• Page Start: 405.e1
• Page End: 405.e9
• Publication Date: 2016-12
• Subjects: Adolescent -- Adults -- Non-seminomatous germ-cell tumors -- SEER -- Testicular cancer; Pediatric urology -- Periodicals; Urologic Diseases -- Periodicals; Urogenital Diseases -- Periodicals; Urologic Surgical Procedures -- Periodicals; Child; Infant; Urologie pédiatrique -- Périodiques; Appareil urinaire -- Maladies -- Périodiques; Pédiatrie; Urologie; Pediatric urology; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); Electronic journals; Periodicals; Electronic journals; 618.926
• DOI: 10.1016/j.jpurol.2016.06.014
• Languages: English
• ISSNs: 1477-5131

Abstract

Summary: Background: In adolescents, approximately 90% of testicular germ cell tumors (T-GCTs) are non-seminomas (NS T-GCTs). Few studies have evaluated the impact of age, specifically in adolescence, on outcomes of NS T-GCTs. Objective: The purpose of this study was to review all patients diagnosed with NS T-GCTs in the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the association between age (adolescents vs. adults) and survival outcomes. Method: The SEER database was queried for individuals ≥13 years old diagnosed with NS T-GCTs from 1995 to 2012. Patients were categorized into adolescent (13–19 years) and adult (≥20 years) cohorts. A Cox proportional hazards model was used for multivariate analysis (MVA). Results: A total of 13, 963 patients (1496 adolescents, 12, 467 adults) was included. Median follow-up was 71 months (range 1–215). Five-year overall survival (OS) for adolescent and adult patients was 94% and 92%, respectively ( p = 0.007); 5-year cancer-specific survival (CSS) was 95% and 94%, respectively ( p = 0.139). Under MVA, adolescent patients had improved OS (HR 0.61; 95% CI 0.50–0.75; p < 0.001) and CSS (HR 0.65; 95% CI 0.51–0.82; p < 0.001), when compared with adults (Table). In a logistic regression analysis adjusting for demographics, adolescent patients were more likely to present with regional or distant metastatic disease (OR 1.16; 95% CI 1.01–1.35; p = 0.039), undergo an orchiectomy (OR 2.44; 95% CI 1.50–4.00; p < 0.001) or tumor excision (OR 2.43; 95% CI 1.57–3.77; p < 0.001), and receive other adjuvant surgery (OR 5.87; 95% CI 2.25–15.30; p < 0.001). Conclusions: To our knowledge, this is the largest population-based comparative analysis in NS T-GCTs comparing outcomes between these two age groups. Adolescent patients with NS T-GCTs had slightly improved survival compared with adults, despite presenting with more advanced disease. While adolescent patients present at more advanced stage, they achieve excellent survival outcomes possibly at the cost of a greater therapeutic burden. Table Multivariate analysis of predictors of cancer-specific survival (CSS). Variable Multivariate HR 95% CI p Age, years ≥20 1 13–19 0.65 0.51–0.82 <0.001 Histology Non-seminomatous germ-cell, NOS 1 Embryonal 0.46 0.34–0.62 <0.001 Yolk sac 0.91 0.62–1.35 0.646 Choriocarcinoma 1.43 1.04–1.96 0.027 Teratoma 0.94 0.63–1.39 0.753 Mixed 0.71 0.54–0.92 0.009 Summary stage Localized 1 Regional/distant 10.35 8.78–12.20 <0.001 Unknown 2.37 1.19–4.72 0.014 HR, hazard ratio; CI, confidence interval; NOS, not otherwise specified.